Paper Details

  1. Home
  2. Paper Details

Emerging oral agents for multiple sclerosis.

Author: FoxEdward J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article reviews the mechanisms of action, efficacy, and safety and tolerability of 4 emerging oral therapies for MS: cladribine, laquinimod, fingolimod, and dalfampridine. Cladribine, laquinimod, and fingolimod have demonstrated impressive efficacy in terms of clinical outcomes, such as annualized relapse rate and change in disability scores, as well as magnetic resonance imaging variables.
Paper Details　
Original Abstract of the Article :
A variety of emerging therapies for the treatment of multiple sclerosis (MS) are currently in development or have recently been approved by the US Food and Drug Administration (FDA). These new agents offer novel mechanisms of action and potentially improved efficacy over existing first-line MS thera...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/20873946

データ提供：米国国立医学図書館（NLM）

Emerging Oral Therapies for Multiple Sclerosis: A New Frontier

Multiple sclerosis (MS) is a complex neurological disorder, like a desert labyrinth, leaving patients navigating a confusing and challenging landscape of symptoms. Researchers are continually searching for effective treatments, and a new frontier has emerged: oral therapies. This article reviews several promising oral therapies currently under development or recently approved for the treatment of MS.

The article examines the mechanisms of action, efficacy, and safety profiles of these new oral therapies, seeking to determine if they offer a more convenient and effective approach to managing MS.

Oral Therapies: Navigating the Desert Labyrinth

Cladribine, laquinimod, fingolimod, and dalfampridine are some of the emerging oral therapies showing promising results in clinical trials. These treatments may offer improved efficacy and convenience over existing therapies, providing a more accessible oasis of relief for MS patients.

Navigating the Desert Labyrinth of MS

The article highlights the importance of ongoing research and careful evaluation of new therapies for MS. While these oral therapies offer hope, it's essential for patients to work closely with their doctors to determine the best treatment strategy, ensuring they find the right path through the desert labyrinth of MS.

Dr.Camel's Conclusion

This article explores the exciting landscape of emerging oral therapies for MS, offering a new path through the desert labyrinth of this complex neurological disorder. These therapies may offer improved convenience and effectiveness, providing a more accessible oasis of relief for MS patients. However, ongoing research and careful evaluation are crucial to ensuring that these treatments are safe and effective for all.

Date :
  1. Date Completed 2011-01-13
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

20873946

DOI: Digital Object Identifier

12711

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.